Ann: Quarterly Activities & Appendix 4C Cash Flow Report, page-2

Well, well, well, sales up, but a fraction of the opperating costs.

Painted a rosy picture of uptake by big pharma while issuing millions of shares and driving down the SP.

Seem to be preparing the company for sale at a fraction of the cost, but grooming SH to accept a sale at P/P/S that makes existing holders think, it could be worse.

Pretty good caper, existing management stay on after the sale to steady the transition and then take a golden handshake when they leave. Fairly standard form in this game.

If I seem negative it is because I am. Looking like a long term grooming exercise from since the Labcon fiasco.

Cant see anything other than a huge loss on this. Come on BCT, prove me wrong.